Effects of oxidized low- and high-density lipoproteins on gene expression of human macrophages

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 6, 2006, Pages 497-508

  Levula, M ^a   Jaakkola, O ^b   Luomala, M ^a   Nikkari, S T ^c   Lehtimaki T ^a,c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

Atherosclerosis; Foam cell; Microarray; ox HDL; ox LDL

Indexed keywords

ANNEXIN; BINDING PROTEIN; COMPLEMENTARY DNA; ENZYME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR 1; HIGH DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; OXIDIZED HIGH DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; STRUCTURAL PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CULTURE MEDIUM; DOWN REGULATION; FOAM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GROWTH; HEMOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; LIPID METABOLISM; MACROPHAGE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION;

EID: 33749026343     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600836651     Document Type: Article

References (48)

1. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462-78.
2. Kruth HS. Macrophage foam cells and atherosclerosis. Front Biosci 2001;6:D429-55.
3. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
4. Zha X, Tabas I, Leopold PL, Jones NL, Maxfield FR. Evidence for prolonged cell-surface contact of acetyl-LDL before entry into macrophages. Arterioscler Thromb Vasc Biol 1997;17:1421-31.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
7. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998;139:205-22.
8. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998;141:1-15.
9. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85:9748-52.
10. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-6.
11. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
13. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 2000;1483:217-35.
14. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
15. Salonen JT, Malin R, Tuomainen TP, Nyyssönen K, Lakka TA, Lehtimäki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. Br Med J 1999;319:487-9; discussion 90.
16. Malin R, Rantalaiho V, Huang XH, Wirta O, Pasternack A, Leinonen JS, et al. Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum Genet 1999;105:179-80.
17. Maier JA, Barenghi L, Pagani F, Bradamante S, Comi P, Ragnotti G. The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein- induced U937/endothelial cell interactions. Eur J Biochem 1994;221:35-41.
18. Nishigaki I, Hagihara M, Tsunekawa H, Maseki M, Yagi K. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 1981;25:373-8.
19. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991;88:6457-61.
20. Hurtado I, Fiol C, Gracia V, Caldu P. In vitro oxidised HDL exerts a cytotoxic effect on macrophages. Atherosclerosis 1996;125:39-46.
21. Greilberger J, Jurgens G. Oxidation of high-density lipoprotein HDL3 leads to exposure of apo-AI and apo-AII epitopes and to formation of aldehyde protein adducts, and influences binding of oxidized low-density lipoprotein to type I and type III collagen in vitro 1. Biochem J 1998;331:185-91.
22. Mikita T, Porter G, Lawn RM, Shiffman D. Oxidized low density lipoprotein exposure alters the transcriptional response of macrophages to inflammatory stimulus. J Biol Chem 2001;276:45729-39.
23. Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC, et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 2004;318:265-74.
24. Jaakkola O, Ylä-Herttuala S, Särkioja T, Nikkari T. Macrophage foam cells from human aortic fatty streaks take up beta-VLDL and acetylated LDL in primary culture. Atherosclerosis 1989;79:173-82.
25. Lehtimäki T, Lehtinen S, Solakivi T, Nikkilä M, Jaakkola O, Jokela H, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-7.
26. Shiffman D, Mikita T, Tai JT, Wade DP, Porter JG, Seilhamer JJ, et al. Large scale gene expression analysis of cholesterol-loaded macrophages. J Biol Chem 2000;275:37324-32.
27. Hiltunen MO, Tuomisto TT, Niemi M, Brasen JH, Rissanen TT, Toronen P, et al. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis 2002;165:23-32.
28. Armstrong PJ, Johanning JM, Calton WC Jr, Delatore JR, Franklin DP, Han DC, et al. Differential gene expression in human abdominal aorta: aneurysmal versus occlusive disease. J Vasc Surg 2002;35:346-55.
29. Niu X, Zammit V, Upston JM, Dean RT, Stocker R. Coexistence of oxidized lipids and alpha-tocopherol in all lipoprotein density fractions isolated from advanced human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1999;19:1708-18.
30. Nakajima T, Origuchi N, Matsunaga T, Kawai S, Hokari S, Nakamura H, et al. Localization of oxidized HDL in atheromatous plaques and oxidized HDL binding sites on human aortic endothelial cells. Ann Clin Biochem 2000;37:179-86.
31. Stocker R. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994;5:422-33.
32. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998;1391:287-306.
33. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 1995;92:4537-41.
34. Willnow TE. Receptor-associated protein (RAP): a specialized chaperone for endocytic receptors. Biol Chem 1998;379:1025-31.
35. Aoyama T, Uchida Y, Kelley RI, Marble M, Hofman K, Tonsgard JH, et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun 1993;191:1369-72.
36. Miller MD, Wilson SD, Dorf ME, Seuanez HN, O'Brien SJ, Krangel MS. Sequence and chromosomal location of the I-309 gene. Relationship to genes encoding a family of inflammatory cytokines. J Immunol 1990;145:2737-44.
37. Haque NS, Zhang X, French DL, Li J, Poon M, Fallon JT, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000;102:786-92.
38. Bernardini G, Spinetti G, Ribatti D, Camarda G, Morbidelli L, Ziche M, et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 2000;96:4039-45.
39. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
40. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
41. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
42. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
43. Salonen JT, Seppänen K, Rauramaa R, Salonen R. Risk factors for carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Med 1989;21:227-9.
44. Belloc F, Hourdille P, Fialon P, Boisseau MR, Soria J. Fibrinogen synthesis by megakaryocyte-rich human marrow cell concentrates. Thromb Res 1985;38:341-51.
45. Uzan G, Courtois G, Stanckovic Z, Crabtree GR, Marguerie G. Expression of the fibrinogen genes in rat megakaryocytes. Biochem Biophys Res Commun 1986;140:543-9.
46. Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood 1997;89:873-82.
47. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995;130:503-6.
48. Hamsten A, Eriksson P. Thrombospondins and premature coronary artery disease: time to go beyond genotype-phenotype association studies. Arterioscler Thromb Vasc Biol 2003;23:6-7.